Descartes Therapeutics

Descartes Therapeutics is a clinical-stage biotechnology company pioneering the development of mRNA-based cell therapies for autoimmune diseases. The company's proprietary RNA Armory platform enables the engineering of cells with RNA to create precision medicines that can be administered in an outpatient setting without the need for lymphodepleting chemotherapy. Its lead product candidate, Descartes-08, is a first-in-class mRNA CAR-T therapy currently in Phase 2 development for generalized myasthenia gravis. By utilizing mRNA instead of DNA, Descartes aims to improve the safety and accessibility of cell therapies for chronic inflammatory and autoimmune conditions.